Euphoria’s Barbie Ferreira put her latest look on display while attending the Academy Women's Luncheon Presented by Chanel in ...

A once-daily oral nonpeptide GLP-1 conferred significant improvements in body weight, HbA1c and other cardiometabolic ...

Trump administration negotiating with Novo Nordisk and Eli Lilly to lower Wegovy, Zepbound prices to $149/month, with some ...

Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

In a small study, patients who have successfully lost weight with weekly GLP-1 treatment maintain their weight loss and ...

Wolfgang goes deep on his great new album as Mammoth, (reluctantly) addresses his feud with David Lee Roth, reveals a weight-loss journey, and more ...

The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.

A once-daily oral quadruple receptor agonist induced up to 13.8% weight loss at 13 weeks among adults with overweight or ...

A deal with Lilly and Novo would be significant for the administration’s push for lower drug prices for Americans.

Detroit Lions hold the final wild-card spot in NFC playoffs. The Eagles remain aggressive at trade deadline as we wait for ...